Mortgage Blog

Amgen plans to buy ChemoCentryx, a one-drug Bay Area biotech, for $3.7 billion

The deal could be a sign of a pick-up in mergers and acquisitions in the Bay Area's biotechnology space.

Previous Bank of America promotes Philly exec with oversight of Pittsburgh market president to bigger role
Next FDA gives Durham's BioCryst green light to resume trial enrollment

Related Posts

Suggested Posts